New 'Living Drug' trial offers hope for Tough-to-Treat lymphoma

NCT ID NCT06486051

First seen Mar 11, 2026 · Last updated Apr 09, 2026 · Updated 7 times

Summary

This trial is testing a new type of personalized cell therapy called WZTL-002 for adults with aggressive large B-cell lymphoma that has come back or not responded to standard chemotherapy. The main goals are to see how well the therapy eliminates the cancer and to monitor its safety, particularly regarding potential effects on brain function. All participants will receive the one-time treatment after a brief course of chemotherapy and will be closely monitored for two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Auckland City Hospital

    RECRUITING

    Auckland, 1023, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Christchurch Hospital

    RECRUITING

    Christchurch, Christchurch Central, 8011, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wellington Hospital

    RECRUITING

    Newtown, Wellington Region, 6021, New Zealand

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.